1798-1799 / 2437
No. Events/No. Patients
Unstratified HR [95% CI]
Nivolumab
Bevacizumab
All patients
154/184
147/185
0.99 [0.79, 1.24]
KPS
> 80%
≤ 80%
91/113
63/71
82/103
64/81
0.94 [0.70, 1.27]
1.13 [0.80, 1.60]
Measurable target lesion
Yes
No
135/153
19/31
130/156
17/29
0.99 [0.78, 1.27]
1.01 [0.52, 1.94]
MGMT
promoter status
Methylated
Unmethylated
Not reported/unknown
33/43
56/59
65/82
31/42
53/67
63/76
0.92 [0.56, 1.51]
1.34 [0.92, 1.96]
0.87 [0.62, 1.23]
Tumor PD-L1 expression
≥ 1%
< 1%
40/48
89/107
28/35
92/114
1.35 [0.83, 2.19]
0.97 [0.72, 1.30]
Dexamethasone equivalent at
baseline
Yes
No
69/73
85/111
68/79
79/106
1.41 [1.01, 1.97]
0.84 [0.62, 1.15]
Favors Nivolumab
Favors Bevacizumab
0
1
2
3
Reardon et al., WFNOS meeting 2017
CheckMate 143
OS in prespecified patient subsets